Poster

Clinical Characteristics and Responses of Patients With Relapsed or Refractory High-Grade B-Cell Lymphoma Treated With Loncastuximab Tesirine in the LOTIS-2 Clinical Trial

Email this document.

Enter your email address below to send this document.

PLACEHOLDER START

[ninja_form id=1]

Important Notice

I am a Healthcare Professional registered to practice in the U.S.
I am a U.S. Patient or Caregiver

key: 1603 val: 40
key: 1564 val: 117
key: 1593 val: 118
key: 1579 val: 119
key: 1575 val: 120
key: 1597 val: 121
key: 1598 val: 127
key: 1570 val: 129
key: 1587 val: 134
key: 1640 val: 135
key: 1600 val: 136
key: 1569 val: 137
key: 1586 val: 138
key: 1591 val: 139
key: 1584 val: 140
key: 1641 val: 141
key: 1588 val: 142
key: 1589 val: 146
key: 1568 val: 147
key: 1566 val: 148
key: 1580 val: 149
key: 1627 val: 152
key: 1595 val: 153
key: 1578 val: 154
key: 1585 val: 158
key: 1594 val: 159
key: 1573 val: 162
key: 1582 val: 163
key: 1572 val: 164
key: 1581 val: 165
key: 1574 val: 170
key: 1616 val: 180
key: 1577 val: 182
key: 1599 val: 183
key: 1567 val: 184
key: 1576 val: 185
key: 1628 val: 189
key: 1604 val: 193
key: 1602 val: 194
key: 1601 val: 203
key: 1590 val: 219
key: 1619 val: 220
key: 1571 val: 221
key: 1583 val: 241
key: 1592 val: 251
key: 1596 val: 253
key: 1618 val: 263
key: 1632 val: 266
key: 1617 val: 269
key: 1621 val: 272
key: 1613 val: 273
key: 1624 val: 276
key: 1620 val: 278
key: 1622 val: 281
key: 1623 val: 287
key: 1605 val: 291
key: 1626 val: 527
key: 1563 val: 530
key: 1625 val: 531
key: 1608 val: 2865
key: 1631 val: 4925
key: 1614 val: 4926
key: 1612 val: 6271
key: 1629 val: 9302
key: 1611 val: 12001
key: 1615 val: 14301
key: 1606 val: 17701
key: 1633 val: 18501
key: 1607 val: 18501
key: 1610 val: 22101
key: 1609 val: 22201
key: 1636 val: 22901
key: 1645 val: 24501
key: 1644 val: 24701
key: 1643 val: 24702Array ( [1603] => 40 [1564] => 117 [1593] => 118 [1579] => 119 [1575] => 120 [1597] => 121 [1598] => 127 [1570] => 129 [1587] => 134 [1640] => 135 [1600] => 136 [1569] => 137 [1586] => 138 [1591] => 139 [1584] => 140 [1641] => 141 [1588] => 142 [1589] => 146 [1568] => 147 [1566] => 148 [1580] => 149 [1627] => 152 [1595] => 153 [1578] => 154 [1585] => 158 [1594] => 159 [1573] => 162 [1582] => 163 [1572] => 164 [1581] => 165 [1574] => 170 [1616] => 180 [1577] => 182 [1599] => 183 [1567] => 184 [1576] => 185 [1628] => 189 [1604] => 193 [1602] => 194 [1601] => 203 [1590] => 219 [1619] => 220 [1571] => 221 [1583] => 241 [1592] => 251 [1596] => 253 [1618] => 263 [1632] => 266 [1617] => 269 [1621] => 272 [1613] => 273 [1624] => 276 [1620] => 278 [1622] => 281 [1623] => 287 [1605] => 291 [1626] => 527 [1563] => 530 [1625] => 531 [1608] => 2865 [1631] => 4925 [1614] => 4926 [1612] => 6271 [1629] => 9302 [1611] => 12001 [1615] => 14301 [1606] => 17701 [1633] => 18501 [1607] => 18501 [1610] => 22101 [1609] => 22201 [1636] => 22901 [1645] => 24501 [1644] => 24701 [1643] => 24702 )
MENU